Focused On-demand Library for Serine/threonine-protein kinase SIK3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Salt-inducible kinase 3; Serine/threonine-protein kinase QSK

Alternative UPACC:

Q9Y2K2; A1A5A8; H0Y494; J3KPC8; Q59FY2; Q5M9N1; Q6P3R6; Q8IYM8; Q9HA50


Serine/threonine-protein kinase SIK3, also known as Salt-inducible kinase 3 and Serine/threonine-protein kinase QSK, plays a pivotal role in mTOR signaling, crucial for chondrocyte differentiation and skeletogenesis. It acts by promoting the degradation of DEPTOR, an inhibitor of mTOR, and negatively regulates the cAMP signaling pathway, impacting cellular processes.

Therapeutic significance:

SIK3's involvement in Spondyloepimetaphyseal dysplasia, Krakow type, a skeletal disorder marked by severe developmental challenges and immunodeficiency, underscores its therapeutic potential. Understanding the role of Serine/threonine-protein kinase SIK3 could open doors to potential therapeutic strategies for treating skeletal dysplasias and related immunodeficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.